Magnevist Lawsuit

Recently, an article published in “Radiology”, has shown that Magnevist and certain other radio-contrast agents used in MRI procedures may leave toxic gadolinium residue in the brain after its use.  Some patients who have received the medication have reported a decrease in ability to think clearly and may be suffering due to gadolinium deposits in the brain.

Magnevist manufacturer, Bayer, has denied responsibility for any injuries.  The company has stated that the studies do not confirm evidence of clinical impact by showing evidence of brain injury to patients.  Experts have recommended additional study as the current results were from examinations done at autopsy, showing gadolinium brain residue in previous MRI patients.

This is not the first time that Bayer has faced lawsuits because of medical injuries caused by Magnevist. Multiple lawsuits were filed against Bayer for the development of a potentially fatal kidney condition known as “nephrogenic systemic fibrosis” (NSF).  Many of these lawsuits were settled out-of-court but Bayer never admitted any wrongdoing.  Now Bayer may be facing multiple lawsuits caused by cognitive damage related to Magnevist use.

Patients who suffer medical injury due to the use of a medication may be eligible for compensation for damages such as medical treatments, lost wages, future medical costs and pain and suffering.  Each potential case of medical injury must be considered independently and filing a lawsuit is no guarantee of compensation but if you or a loved one has been injured by Magnevist use, your case should be evaluated by legal experts.

Magnevist Toxic Brain Residue

Magnevist is known as a “gadolinium-based contrast agent” (GBCA).  Recent studies published in Radiology magazine, a well-respected medical journal have shown that gadolinium, the toxic core of GBCA’s like Magnevist may be left as a residue in the brains of patients who have had multiple MRI procedures.

Gadolinium is known to be toxic and even though previous evidence showed that it may be deposited in bone, skin and other body tissues of patients with severe kidney damage, this is the first time that gadolinium has been found in brain tissue.  In addition, the results of the studies are particularly troubling as the deposits were found in patients who did not have damaged kidneys.

Some patients who have received multiple doses of Magnevist, have reported that they have experienced significant declines in cognitive or though processing.  This has impaired the ability to perform normal daily functions and has resulted in job loss.  Some of these patients have formed support groups, including one on Facebook, to discuss and seek help for physical symptoms caused by Magnevist use.

Bayer, the manufacturer of Magnevist, has denied any fault, stating that no evidence of “clinical” impairment has been shown but it is notable that study results were obtained upon autopsy of previous Magnevist patients.  Bayer was previously implicated in Magnevist medical injury and though they settled many lawsuits, they continued to deny responsibility.

About Gadolinium-based Contrast Agents (GBCAs)

Gadolinium has been shown to be toxic in animal studies and even though it has dramatically improved diagnostic imaging capability, it has also been shown to be toxic in some patients.  Recent evidence shows the threat may be larger than previously thought.

Magnevist, the first GBCA, has a “linear” chemical structure but newer agents have a “cage-like” chemical structure, which may make them safer as the “cage” may prevent the gadolinium molecule from being deposited in patient tissues such as the brain.

Though Magnevist was the first GBCA, Bayer invented a newer produce, Gadovist.  The newer “macrocyclic” or cage-like agent was introduced in Europe in the late 1990’s but even though the company already knew about potential renal toxicity, they did not bring the safer drug to the U.S. until 2010.  Some experts have long recommended that only the “safer” agents be used, unfortunately many U.S. physicians were not given the Gadovist option.

About Magnevist

Magnevist is manufactured by Bayer, a Germany-based pharmaceutical giant which has estimated annual revenue of $44 billion.  Magnevist contains the gadolinium substance, gadopentetic dimeglumine.   It was the first gadolinium type contrast agent to be approved in 1987.  Even though newer, potentially safer agents have been available in Europe since the late 90’s, including another Bayer product, Gadovist, Bayer did not choose to market Gadovist in the U.S. until 2010, well after major problems with older agents had surfaced.

In 1997, a severe condition known as “nephrogenic systemic fibrosis” was identified but no cause was known.  In 2001, gadolinium contrast agents were suspected in several cases of renal injury but the two conditions were not connected until 2006 when a Danish physician connected NSF cases to gadolinium use.  The Danish Medicines Agency initially identified 25 cases of NSF linked to gadolinium-based contrast agents, later expanding this number to over 150.

Though GE, the manufacturer of another GBCA, attempted to discredit the Danish physician by claiming libel and reporting bias, filing suit against him in UK High Court, the Commission on Human Medicines in the UK issued an advisory about the medications, warning against their use in really-compromised patients.

The FDA followed with a 2007 warning to U.S. physicians regarding NSF and required that a “black box” warning be added to gadolinium-based agents including Magnevist.  Experts had recommended that the products be prohibited for use in kidney patients but that advice was not taken until 2010 when the FDA recommended that Magnevist not be used at all in patients with known kidney damage.

Since the ban on use in kidney patients, few additional NSF cases have surfaced but new studies show that the drug is potentially harmful to non-kidney patients, with the possibility of toxic gadolinium passing into the brain and being left there.

Side Effects of Magnevist

All medications, including contrast agents cause side effects.  Most of the side effects are mild and usually temporary but some may be more serious or life-threatening.

Mild to moderate side effects of Magnevist may include:

  • Dizziness
  • Headache
  • Nausea
  • Unpleasant aftertaste
  • Hot flash, flushing or cold sensation

More serious side effects may include

  • Allergic reactions such as:
    • Rash
    • Swelling
    • Difficulty breathing
    • Anaphylaxis
  • Renal symptoms such as
    • Urinary urgency and incontinence
    • Swelling of extremities
    • Extreme thirst
  • Nephrogenic Systemic Fibrosis symptoms such as
    • Raised plaques or papules
    • Colored skin areas
  • Neurological symptoms such as
    • Confusion
    • Loss of thought patterns
    • Speech disorder
    • Seizure
    • Coma

Serious adverse events should be immediately reported to medical personnel and may be considered to be an emergency.

View Sources
  1. American Pharmacists Association, (22 June 2015), I.V. drug used during an MRI leaves toxic metal residue, Pharmacists.com, Accessed on 08 July 2015 http://www.pharmacist.com/iv-drug-used-during-mri-leaves-toxic-metal-residue
  2. Anderson, P., (26 March 2015), Gadolinium Found in Brain Tissue, Medscape, Accessed on 08 July 2015 http://www.medscape.com/viewarticle/842107
  3. Bayer AG, (2014), Bayer Annual Report 2013, Bayer.com, Accessed on 08 July 2015 http://www.annualreport2013.bayer.com/en/overview.aspx
  4. Bayer AG, (26 March 2015), Bayer receives approval for Gadovist® (gadobutrol) injection in Japan (not intended for U.S. and UK Media), Accessed on 08 July 2015 http://press.healthcare.bayer.com/en/press/news-details-page.php/15809/2015-0092
  5. Bayer Healthcare, (2015), Magnevist Prescribing Information, Bayer AG, Accessed on 08 July 2015 http://labeling.bayerhealthcare.com/html/products/pi/Magnevist_PI.pdf
  6. Calamante, F., et al., (December 2003 ), Quantification of bolus-tracking MRI: Improved characterization of the tissue residue function using Tikhonov regularization, Magnetic Resonance in Medicine, Accessed on 08 July 2015 http://www.researchgate.net/publication/5924715_Quantification_of_bolus-tracking_MRI_Improved_characterization_of_the_tissue_residue_function_using_Tikhonov_regularization
  7. Drugs.com, (2015), History of Gadavist, Drugs.com Accessed on 08 July 2015 http://www.drugs.com/history/gadavist.html
  8. Essig, M., (November 2002), Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers, Radiologe, Accessed on 08 July 2015 http://www.ncbi.nlm.nih.gov/pubmed/12458444
  9. Food and Drug Administration, (May 2007), Questions and Answers on Gadolinium-Based Contrast Agents, U.S. Food and Drug Administration, Accessed on 08 July 2015 Accessed on 08 July 2015 http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm
  10. Food and Drug Administration, (23 May 2007), FDA Requests Boxed Warning for Contrast Agents Used to Improve MRI Images, U.S. Food and Drug Administration, Accessed on 08 July 2015 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108919.htm
  11. Food and Drug Administration, (December 2010), FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. U.S. Food and Drug Administration, Accessed on 08 July 2015 http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm142889.htm
  12. Food and Drug Administration, (15 March 2011), FDA approves imaging agent for central nervous system scans, U.S. Food and Drug Administration, Accessed on 08 July 2015 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm247207.htm
  13. Food and Drug Administration, (October 2013), FDA Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Accessed on 08 July 2015 http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm238544.htm
  14. Forrest, W., (21 January 2011), FDA panel gives nod to Bayer's Gadovist MRI contrast agent, Aunt Minnie, Accessed on 08 July 2015 http://www.auntminnie.com/index.aspx?sec=ser&sub=def&pag=dis&ItemID=93935
  15. Gerth, J., (19 December 2009), GE Suit Hushes Scientist Critical of Omniscan, ProPublica, Accessed on 08 July 2015 http://www.propublica.org/article/ges-omniscan-lawsuit-ratchets-up-volume-in-british-libel-debate-1219
  16. Gerth, J., (12 June 2015), Left in the Brain: Potentially Toxic Residue From MRI Drugs, ProPublica, Accessed on 08 July 2015 http://www.truth-out.org/news/item/31346-left-in-the-brain-potentially-toxic-residue-from-mri-drugs
  17. Hocter, J., (30 March 2015), Problems with ‘picture juice’? Gadolinium contrast deposits raise concerns, Health Imaging, Accessed on 08 July 2015 http://www.healthimaging.com/topics/practice-management/problems-%E2%80%98picture-juice%E2%80%99-gadolinium-contrast-deposits-raise-concerns
  18. ICNSFR, (15 June 2013), NSF – What is it?, The International Center for Nephrogenic Systemic Fibrosis Research (ICNSFR), Accessed on 08 July 2015 http://www.icnfdr.org/
  19. Kanal, E., et al., (June 2015), Residual or Retained Gadolinium: Editorial, Radiology, Accessed on 08 July 2015 pubs.rsna.org/doi/pdf/10.1148/radiol.2015150805
  20. Naganawa, S., et al., (September 2010), Estimation of gadolinium-induced T1-shortening with measurement of simple signal intensity ratio between the cochlea and brain parenchyma on 3D-FLAIR: correlation with T1 measurement by TI scout sequence, Magnetic Resonance Medical Science (Japan), Accessed on 08 July 2015 http://www.ncbi.nlm.nih.gov/pubmed/20339262
  21. Mehndiratta, A., et al., (23 December 2013) Modeling the residue function in DSC-MRI simulations: analytical approximation to in vivo data, Magnetic Resonance Medicine, Accessed on 08 July 2015 http://www.ncbi.nlm.nih.gov/pubmed/24443102
  22. National Library of Medicine, (2015), Gadobutrol (Injection), National Institute of Health, Accessed on 08 July 2015 http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0010423/
  23. PR News, (28 November 2003), Schering receives EU approval for Gadovist(R)1.0 in Magnetic Resonance Angiography, PR News Wire, Accessed on 08 July 2015 http://www.prnewswire.com/news-releases/schering-receives-eu-approval-for-gadovistr10-in-magnetic-resonance-angiography-73145917.html
  24. Reuters News, (16 April 2009), Bayer settles some Magnevist lawsuits, Reuters Frankfurt, Accessed on 15 July 2015 http://www.reuters.com/article/2009/04/16/bayer-settlement-idUSLG38297720090416
  25. Scutti, S., (16 June 2015), IV Drip Drug Used During An MRI Leaves Behind Toxic Metal Residue In Brains Of Patients, Medical Daily, Accessed on 08 July 2015 http://www.medicaldaily.com/iv-drip-drug-used-during-mri-leaves-behind-toxic-metal-residue-brains-patients-338440
  26. Sheller, J., (04 March 2010), Nephrogenic Systemic Fibrosis Settlements Reached by Bayer in 140 Cases, Legal Examiner, Accessed on 15 July 2015 http://philadelphia.legalexaminer.com/fda-prescription-drugs/settlement-of-some-magnevist-lawsuits/
  27. Silvio, Aime, et al., (December 2009), Biodistribution of gadolinium-based contrast agents, including gadolinium deposition, Journal of Magnetic Resonance Imaging, Accessed on 08 July 2015 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822463/